Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

ATHA Athira Pharma Inc

Price (delayed)

$0.2597

Market cap

$10.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.07

Enterprise value

-$15.8M

Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira aims to provide rapid cognitive ...

Highlights
ATHA's quick ratio has soared by 72% from the previous quarter and by 42% YoY
The EPS is up by 32% YoY and by 18% QoQ
ATHA's equity has plunged by 65% YoY and by 17% from the previous quarter

Key stats

What are the main financial stats of ATHA
Market
Shares outstanding
39.04M
Market cap
$10.14M
Enterprise value
-$15.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.27
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$82.75M
Net income
-$79.75M
EBIT
-$79.75M
EBITDA
-$78.53M
Free cash flow
-$86.06M
Per share
EPS
-$2.07
EPS diluted
-$2.07
Free cash flow per share
-$2.2
Book value per share
$0.96
Revenue per share
$0
TBVPS
$1.11
Balance sheet
Total assets
$43.51M
Total liabilities
$6.18M
Debt
$1.12M
Equity
$37.33M
Working capital
$34.36M
Liquidity
Debt to equity
0.03
Current ratio
7.26
Quick ratio
6.79
Net debt/EBITDA
0.33
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-106.4%
Return on equity
-143%
Return on invested capital
N/A
Return on capital employed
-209.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ATHA stock price

How has the Athira Pharma stock price performed over time
Intraday
-7.25%
1 week
8.84%
1 month
-0.04%
1 year
-88.2%
YTD
-55.74%
QTD
-8.85%

Financial performance

How have Athira Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$82.75M
Net income
-$79.75M
Gross margin
N/A
Net margin
N/A
ATHA's operating income is up by 33% YoY and by 18% from the previous quarter
ATHA's net income is up by 31% year-on-year and by 18% since the previous quarter

Price vs fundamentals

How does ATHA's price correlate with its fundamentals

Growth

What is Athira Pharma's growth rate over time

Valuation

What is Athira Pharma stock price valuation
P/E
N/A
P/B
0.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 32% YoY and by 18% QoQ
ATHA's P/B is 75% below its 5-year quarterly average of 1.1 and 55% below its last 4 quarters average of 0.6
ATHA's equity has plunged by 65% YoY and by 17% from the previous quarter

Efficiency

How efficient is Athira Pharma business performance
ATHA's return on equity has dropped by 77% year-on-year and by 8% since the previous quarter
Athira Pharma's ROA has plunged by 57% YoY and by 7% from the previous quarter

Dividends

What is ATHA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATHA.

Financial health

How did Athira Pharma financials performed over time
ATHA's total liabilities has dropped by 77% year-on-year and by 56% since the previous quarter
Athira Pharma's current ratio has soared by 74% from the previous quarter and by 44% YoY
The company's debt is 97% lower than its equity
The company's debt to equity has surged by 200% YoY
ATHA's equity has plunged by 65% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.